SPOTLIGHT: Big Pharma takes an interest in cancer vaccines

For two decades, companies have struggled to develop therapeutic vaccines designed to treat cancer by stimulating the immune system to attack cancer cells without harming normal cells. So far, the FDA has yet to approve a single therapeutic cancer vaccine. But a crop of late-stage cancer vaccines are showing a lot of promise and attracting the attention of pharma and biotech companies. Check out this report for a look at some of the late-stage drug candidates that could revolutionize the cancer treatment field. Article

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.